DISRUPT CAD IV

This Shockwave coronary study demonstrates the safety and effectiveness of Shockwave coronary IVL within a Japanese population.

See Full 30-Day Results See Full 1-Year Follow-Up Results
DISRUPT CAD IV logo
DISRUPT CAD IV logo

Study Leadership

This section contains attributions including profile pictures, titles, descriptions, and Twitter handles.

  • Shigeru Saito, MD, FACC, FSCAI, FJCC
    Director of the Department of Cardiology and Catheterization Laboratory Shonan Kamakura General Hospital Kamakura, Japan

DISRUPT CAD IV Key Findings

  • Low rates of major adverse cardiac events (MACE) at 30-day (6.3%) and 1-year (9.4%) follow-up 
  • High degree of procedural success (98.4%) defined by residual stenosis <50% without in-hospital MACE 
  • No perforations, slow flow, no-reflow, or major (Type D-F) dissections 
  • Low and remarkably consistent 30-day and 1-year target lesion failure at 6.3% 

Statistics Callout

This section presents key statistical information with numbers and descriptions.

  • 64
    Patients at eight sites
  • 100
    %
    Severe Ca++
  • 50 mm
    Calcium length
  • 258
    °
    Calcium angle
  • 0
    %
    Major dissections
  • 0
    %
    Perforations
  • 0
    %
    Abrupt closures
  • 0
    %
    Slow/no reflow
  • 100
    %
    Stent delivery
  • 99
    %
    Stent expansion at max calcium site
  • 94
    %
    Procedural success
  • 5.7 mm
    2
    Minimum stent area
See All Clinical Evidence
See All Clinical Evidence
  • DISRUPT CAD I
    Single-arm, pre-market study demonstrating the safety and performance of Shockwave IVL in heavily calcified coronary lesions.
    Coronary IVL
  • DISRUPT CAD II
    European post-market study confirming DISRUPT CAD I results and showing strong safety and procedural success with Shockwave coronary IVL.
    Coronary IVL
  • DISRUPT CAD III
    Largest and most rigorous Shockwave study showcasing safety, effectiveness and ease of use of Shockwave coronary IVL. 
    Coronary IVL